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Bim is known to be critical in killing of melanoma cells by inhibition of the RAF/MEK/ERK pathway. However, the potential role of
the most potent apoptosis-inducing isoform of Bim, BimS, remains largely unappreciated. Here, we show that inhibition of the
mutant B-RAF
V600E triggers preferential splicing to produce BimS, which is particularly important in induction of apoptosis in
B-RAF
V600E melanoma cells. Although the speciﬁc B-RAF
V600E inhibitor PLX4720 upregulates all three major isoforms of Bim,
BimEL,BimL,andBimS,atthe protein andmRNA levelsinB-RAF
V600Emelanoma cells, theincreaseintheratios ofBimSmRNA to
BimEL and BimL mRNA indicates that it favours BimS splicing. Consistently, enforced expression of B-RAF
V600E in wild-type
B-RAFmelanomacellsandmelanocytesinhibits BimSexpression.Thesplicingfactor SRp55appearsnecessaryfortheincrease
in BimS splicing, as SRp55 is upregulated, and its inhibition by small interfering RNA blocks induction of BimS and apoptosis
induced by PLX4720. The PLX4720-induced, SRp55-mediated increase in BimS splicing is also mirrored in freshly isolated
B-RAF
V600E melanoma cells. These results identify a key mechanism for induction of apoptosis by PLX4720, and are instructive
for sensitizing melanoma cells to B-RAF
V600E inhibitors.
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Results from clinical studies with small molecule inhibitors
of the mutant B-RAF
V600E have been very encouraging,
and promise to provide a much needed breakthrough in the
treatment of melanoma by targeting B-RAF
V600E.
1,2 The latter
is found in B50% of melanomas, leading to constitutive
activation of the RAF/MEK/ERK pathway that is important
for melanoma cell growth and survival, and is involved in
resistance to many therapeutic approaches.
3,4 However, a
number of questions have already been raised from these
studies, such as the durability of responses and why some
melanomas with mutant B-RAF have not shown major
responses.
1,2
It is well established that blockade of the RAF/MEK/ERK
pathway inhibits melanoma cell growth.
5 In addition, a more
desirable outcome, induction of apoptosis, has also been
shown in varying in vitro systems, in particular, in B-RAF
V600E
melanoma cells.
6–10 Apoptosis of such cells was clearly
demonstrated in an ex vivo model after administration of the
B-RAF inhibitor, PLX4720, that is selective for the mutant
B-RAF
V600E6. Consistently, regression of metastatic mutant
B-RAF melanomas is a frequent sign of the response to
administration of PLX4032, a close analogue to PLX4720,
1,2
suggesting that induction of apoptosis may be a major
biological consequence of inhibition of mutant B-RAF.
Several mechanisms have been reported to contribute
to apoptosis induced by inhibition of the RAF/MEK/ERK path-
way. These include dephosphorylation of Bad, translocation of
Bmf, upregulation of BimEL, and downregulation of Mcl-1.
7–11
Among them, upregulation of BimEL via inhibition of its phos-
phorylation and subsequent proteasomal degradation may be
the best documented
7,8 and is of particular interest, in that Bim,
unlikeothermoreselectiveBcl-2homology3(BH3)-onlyproteins
such as Bad and Bmf, can bind with high afﬁnity to and inhibit all
prosurvival Bcl-2 family proteins.
12 In addition, Bim can directly
bind to and activate Bax.
12 It is of note that besides posttrans-
lational changes, inhibition of the RAF/MEK/ERK pathway has
also been shown to cause upregulation of Bim mRNA.
13
There are three major isoforms of Bim, BimEL, BimL, and
BimS, that are generated by alternative splicing.
14 Although
BimS is encoded by exons 2, 5, and 6, BimL is encoded by
exons 2,4,5,and6,andBimELbyexons2,3,4,5,and 6.Both
BimL and BimEL contain a binding site for dynein light
chain 1,
14,15 hence, their proapoptotic activity is controlled
by sequestration to the cytoskeleton-associated dynein motor
complex.
15 Because exon 3 encodes an ERK1/2-docking
domain and ERK1/2 phosphorylation sites, BimEL is subject to
phosphorylation by the MEK/ERK pathway that targets it for
proteasomal degradation and also prevents its binding to
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16 BimS is not subject to any known posttranslational
regulationandisthemostpotentapoptosisinduceramongthe
three isofoms.
13,16,17
Alternative splicing is a tightly regulated process that gene-
rates multiple functional variants from individual genes, thus
enhancing protein diversity.
18 Alternative splicing patterns are
frequently altered in cancer cells, resulting in aberrant
expression of mRNA and protein variants that have been
proposed to have unique properties to confer biological
characteristics of the cells.
19–22 The splicing process is
catalyzed by the spliceosome that is composed of cis-acting
elements, such as splicing enhancers and silencers, and
trans-acting factors, including the serine/arginine-rich (SR)
and heterogeneous ribonucleoprotein particle (hnRNP)
Figure 1 PLX4720 inhibits proliferation and induces apoptosis in mutant B-RAF melanoma cells. (a) Whole cell lysates from Mel-RM (wild-type B-RAF) and Mel-RMu
(B-RAF
V600E) cells treated with PLX4720 at indicated concentrations for 72h (upper panel) or at 10mM for indicated periods (lower panel), were subjected to western blot
analysis of phosphorylated ERK1/2 and ERK1/2. (b) Mel-RM and Mel-RMu cells were treated with PLX4720 at indicated concentrations for 72h. Cell viability (left panel) and
apoptosis(rightpanel)werequantitatedbytheMTSassayandpropidiumiodide(PI)method,respectively.Thedatashownarethemean±S.E.ofthreeindividualexperiments.
(c)Mel-RMandMel-RMucellsweretreatedwithPLX4720at10mMforindicatedperiods.Cellviability(leftpanel)andapoptosis(rightpanel)werequantitatedbytheMTSassay
andPI method, respectively. Thedata shown are themean±S.E. of three individual experiments. (d) A summary of the effect of PLX4720 on cell survival in a panel of mutant
andwild-typeB-RAFmelanomacell lines.CellstreatedwithPLX4720at10mMfor72hweresubjectedtoMTSassays.Thedatashownarethemean±S.E.ofthreeindividual
experiments. (e) Left panel: B-RAF
V600E Mel-RMu and Mel-CV cells were transfectedwith thecontrol or B-RAF siRNA. After 24h, whole cell lysates were subjected to western
blot analysisof B-RAF,phosphorylated ERK1/2, andERK1/2. Western blot analysis of A-RAFandC-RAFwas includedas controls to showthespeciﬁcity of theB-RAFsiRNA.
Rightpanel:Mel-RMuandMel-CVcellsweretransfectedwiththecontrol orB-RAFsiRNA.After24h,cellsweretreatedwithPLX4720(10mM)forafurther72h.Apoptoticcells
were measured by the PI method. The data shown are either representative (left panel), or the mean±S.E. (right panel), of three individual experiments
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Cell Death and Diseaseprotein families. SR proteins are characterized by one or two
RNA recognition motifs at the N-terminal and have an
important part in splice-site selection through association with
splicing enhancers and silencers.
18 Changes in the expres-
sion of a number of SR proteins have been found in various
types of cancer cells.
23–26
To better understand the mechanism(s) by which inhibition
of B-RAF
V600E induces apoptosis of melanoma cells, we have
examined completely the apoptotic response of B-RAF
V600E
melanoma cells to the B-RAF
V600E inhibitor PLX4720. We
show in this report that preferential splicing to produce BimS
has an important role in induction of apoptosis by PLX4720 in
B-RAF
V600E melanoma cells. Moreover, we demonstrate that
the increase in BimS splicing is mediated by the SR protein,
SRp55.
Results
The B-RAF
V600E inhibitor PLX4720 induces apoptosis in
B-RAF
V600E melanoma cells. Our initial studies conﬁrmed
that the small molecule compound PLX4720 is speciﬁc for
inhibition of B-RAF
V600E. This was shown by its inhibitory
effect on ERK activation in B-RAF
V600E melanoma cell lines,
but not in those carrying the wild-type B-RAF even when
it was used at 10mM (Figure 1a and Supplementary
Figure 1A). The inhibitory effect of PLX4720 at 10mMo n
activation of ERK was sustained till 72h after treatment
(Figure 1a). Examination of the effect of PLX4720 on cell
growth similarly demonstrated that it inhibited proliferation of
B-RAF
V600E melanoma cells, but had only minimal effects
on growth of those harboring the wild-type B-RAF (Figure 1b
and Supplementary Figures 1B).
We examined whether induction of apoptosis was involved
in PLX4720-mediated inhibition of cell growth in Mel-RMu
(B-RAF
V600E) and Mel-RM (wild-type B-RAF) cells. At
concentrations of up to 1mM, PLX4720 did not induce
signiﬁcant apoptosis by 72h (Figure 1b). At 3mM, it induced
apoptosis in B30% of Mel-RMu cells, but apoptosis in Mel-RM
cells remained marginal. When it was used at 10mM, 465%
of Mel-RMu cells and B20% of Mel-RM cells underwent
apoptosis, which corresponded well with the efﬁciency of inhi-
bition of cell viability in both cell lines (Figure 1b). Predominant
induction of apoptosis by PLX4720 at 10mM was conﬁrmed by
treating the cells with the compound at the same concentration
for varying time periods (Figure 1c). This was also shown by
activation of caspase-3 and -7, and cleavage of the caspase-3
substrate PARP (Supplementary Figure 2).
Studies in a panel of melanoma cell lines indicated that
B-RAF
V600E lines were, in general, signiﬁcantly more sen-
sitive to PLX4720 than those harboring the wild-type B-RAF
(Po0.01; two-tailed student’s t-test) (Figure 1d). Similar to
PLX4720, Small interfering RNA (siRNA) knockdown of
B-RAF induced apoptosis in two B-RAF
V600E melanoma cell
lines, indicating that induction of apoptosis by PLX4720 is due
to inhibition of B-RAF
V600E (Figure 1e).
PLX4720 preferentially enhances splicing of BimS.
Overexpression of Bcl-2 inhibited induction of apoptosis by
PLX4720 in B-RAF
V600E melanoma cells, indicating that the
Figure 1 Continued
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Cell Death and Diseasemitochondrial apoptotic pathway is essential in PLX4720-
induced apoptosis (Figure 2a). In support of this, treatment
with PLX4720 resulted in activation of Bax, and mitochondrial
release of cytochrome c and apoptosis-inducing factor (AIF)
(Supplementary Figure 3). These results suggest that
activation of one or more BH3-only proteins of the Bcl-2
family is important in initiating PLX4720-mediated apoptotic
signaling.
27 As shown in Figure 2b, PLX4720 caused
upregulation of the Bim isoforms, BimEL, BimL, and BimS,
in B-RAF
V600E Mel-RMu cells, but not in wild-type B-RAF
Mel-RM cells. In particular, the increase in BimS was most
prominent and sustained. The changes in BimEL expression
was associated with reduction in the levels of an extra band,
with reduced electrophoretic motility that corresponds to
phosphorylated BimEL.
13 Of note, PLX4720 also induced a
novel protein product with an apparent molecular weight
between BimL and BimS at 36h after treatment (Figure 2b).
In contrast to regulation of Bim, PLX4720 did not cause any
signiﬁcant changes in other Bcl-2 family proteins analyzed,
except for downregulation of the anti-apoptotic proteins Mcl-1
and Bcl-2 at relatively late stages (36h after treatment) in
Mel-RMu cells (Figure 2b). Regulation of Bim by PLX4720
was conﬁrmed in another three B-RAF-mutant melanoma
cell lines (Supplementary Figure 4).
The marked increase in BimS induced by PLX4720 was
intriguing because, unlike BimEL and BimL, this isoform is not
regulated by any known posttranslational mechanisms.
13,15
We reasoned that upregulation of BimS is a consequence
of enhanced Bim transcription and a subsequent increase
in splicing to produce BimS. To test this, we ﬁrst quantitated
the Bim mRNA expression before and after exposure to
PLX4720. As shown in Figure 2c, PLX4720 triggered a rapid
and sustained increase in Bim mRNA in Mel-RMu cells, which
could be efﬁciently inhibited by pretreatment with actinomycin
D (Figure 2c), suggesting that this was due to a transcriptional
increase, rather than a change in the mRNA stability.
We next monitored the levels of the three major Bim mRNA
species in Mel-RMu cells before and after exposure to
PLX4720 in qPCR analysis. Figure 3a shows that, although
they were all increased by treatment with PLX4720, the ratio
Figure 2 PLX4720 upregulates Bim. (a) Upper panel: overexpression of Bcl-2 in Mel-RMu and Mel-CV cells stably transfected with cDNA encoding Bcl-2. Whole cell
lysates were subjected to western blot analysis of Bcl-2 and GAPDH (as a loading control). Lower panel: Mel-RMu and Mel-CV cells overexpressing Bcl-2 were treated with
PLX4720 (10mM) for 72h before apoptosis was quantitated by the propidium iodide (PI) method. The data shown are either representative (upper panel) or mean±S.E.
(lowerpanel)ofthreeindividualexperiments.(b)WholecelllysatesfromMel-RMandMel-RMucellstreatedwithPLX4720(10mM)forindicatedtimeperiodsweresubjectedto
western blot analysisof Bim, Bid, PUMA, Noxa, Bax, Bak, Mcl-1, Bcl-2, and GAPDH (as a loading control). The data shown are representativeof three individual western blot
analyses. (c) Left panel: total RNA from Mel-RM and Mel-RMu cells treated with PLX4720 (10mM) for indicated time periods was isolated and subjected to real-time PCR
analysis for Bim mRNA expression. The relative abundance of mRNA expression before treatment was arbitrarily designated as 1. Right panel: total RNA from Mel-RM
and Mel-RMu cells treated with PLX4720 (10mM) for 16h with or without pretreatment with actinomycin D (Act-D) (3mg/ml) for 1h were subjected to real-time PCR analysis.
The relative abundance of mRNA expression before treatment was arbitrarily designated as 1. The data shown are the mean±S.E. of three individual experiments
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Cell Death and Diseaseof BimS mRNA to BimEL mRNA in Mel-RMu cells after
treatment for 16h was four times higher than that before
treatment (Figure 3b). Similarly, the ratio of BimS mRNA to
BimL mRNA was also increased, although to a lesser extent
(Figure 3b). The increase in BimS mRNA relative to BimEL and
BimL mRNA was conﬁrmed in an additional three B-RAF-
mutant melanoma cell lines (Supplementary Figure 5).
Collectively, these results suggest that PLX4720 may cause
preferential splicing to produce BimS.
To conﬁrm that the increase in BimS splicing is speciﬁc to
inhibition of B-RAF
V600E by PLX4720, we treated Mel-RMu
and Mel-RM cells with the histone deacetylase inhibitor
suberic bishydroxamate (SBHA), which is known to upregu-
late Bim at the transcriptional level.
28 Figure 3c shows that, as
reported before, the Bim mRNA and protein levels were
upregulated by SBHA in melanoma cells, regardless of their
B-RAFmutationalstatus.Althoughthisincreasewasreﬂected
at the levels of the three Bim mRNA species, the ratios of the
BimS mRNA to the BimEL and BimL mRNA in both cell lines
before and after treatment remained unaltered (Figure 3d).
Enforced expression of B-RAF
V600E inhibits Bimsexpression
in melanocytes and melanoma cells. We transfected
cDNA encoding B-RAF
V600E into wild-type B-RAF Mel-RM
and Me1007 cells. Enforced expression of B-RAF
V600E resulted
in increases in activation of ERK (Figure 4a). Because the three
Bim protein variants were all constitutively expressed at low levels
in both cell lines, it was not feasible to judge whether enforced
expression of B-RAF
V600E resulted in downregulation of the
proteins. To overcome this limitation, we treated the cells
transfected with B-RAF
V600E with SBHA, and monitored
changes in the three mRNA species. Figure 4b shows that
enforced expression of B-RAF
V600E blocked increases in BimS
mRNA induced by SBHA. Inhibition of SBHA-mediated induction
of BimS by enforced expression of B-RAF
V600E was also mirrored
at the protein level (Figure 4c).
The effect of B-RAF
V600E on the expression of the three
Bimisoforms wasalsoexamined inaculturedmelanocyte line
that was transfected with cDNA encoding B-RAF
V600E. It was
notable that the BimEL, BimL, and BimS proteins were all
constitutively expressed at detectable, although moderate,
Figure 3 PLX4720 preferentially increases splicingto produceBimS.( a) Total RNA from Mel-RMu cells treated with PLX4720 (10mM) for 16h was subjected to real-time
PCR analysis for BimEL, BimL, and BimS mRNA expression. The levels of the expression of individual species before treatment were arbitrarily designated as 1. The data
shownare themean±S.E.ofthreeindividualexperiments.(b)TotalRNAfromMel-RMucellstreatedwithPLX4720(10mM) for16hwassubjectedto BimEL,BimL,andBimS
mRNA expression as in a. Left panel: the ratios between the levels of BimS mRNA and BimEL mRNA before and after treatment, respectively, were calculated as
(DDCt of BimS/DDCt of BimEL). Right panel: the ratios between the levels of BimS mRNA and BimL mRNA before and after treatment, respectively, were calculated as
(DDCt of BimS/DDCt of BimL). Thedata shown are themean±S.E. of three individualexperiments. (c) Upperpanel: totalRNA fromMel-RM andMel-RMucells treatedwith
SBHA (10mg/ml) for 16h were subjected to real-time PCR analysis for Bim mRNA expression. The relative abundance of mRNA expression before treatment was arbitrarily
designatedas1.Lowerpanel:wholecelllysatesfromcellstreatedasaboveweresubjectedtowesternblotanalysisofBimandGAPDH(asaloadingcontrol).Thestrongband
denoted by the arrowhead is nonspeciﬁc, and was associated with the particular batch of the antibody against Bim used in the experiment. The data shown are either
representative(lowerpanel)orthemean±S.E.(upperpanel)ofthreeindividualexperiments.(d)TotalRNAfromMel-RMandMel-RMucellstreatedwithSBHA(10mg/ml)for
16h were subjected to real-time PCR analysis for BimEL, BimL, and BimS mRNA expression. The ratios of BimS mRNA to BimEL and BimL mRNA before and after treatment,
respectively, were calculated as in b. The data shown are the mean±S.E. of three individual experiments
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Cell Death and Diseaselevels in cultured melanocytes (Figure 4d). Survival of
melanocytes in the presence of these Bim isoforms is
conceivable owing to sequestration of BimEL and BimL in the
cytoskeleton,
13,14 and neutralization of BimS by anti-apoptotic
Bcl-2 family proteins (Figure 4d).
12 Consistent with its
inhibitory effect on the expression of BimS in melanoma cells,
enforced expression of B-RAF
V600E caused a decrease in this
isoform in melanocytes (Figure 4d). Intriguingly, there was an
increase in the levels of BimL in melanocytes transfected with
B-RAF
V600E, suggesting that the effect of B-RAF
V600E on
regulation of Bim expression may be more complex than just
impingingonBimELandBimS,andmayvarybetweendifferent
types of cells.
BimS has a dominant role in apoptosis of B-RAF
V600E
melanoma cells induced by PLX4720. To examine the
relative importance of BimEL and BimS in PLX4720-induced
apoptosis, we transfected siRNA speciﬁc for Bim in general,
BimEL, and BimS into Mel-RMu cells (Figures 5a–c). Although
siRNA knockdown of BimEL inhibited PLX4720-induced
apoptosis by 30%, inhibition of BimS by siRNA blocked
apoptosis induction by PLX4720 by 56% (Figure 5d). These
results indicate that both BimEL and BimS are involved in
induction of apoptosis of B-RAF
V600E melanoma cells by
PLX4720, but BimS has a greater part than BimEL. Although
we did not speciﬁcally measure the role of BimL because of
technical limitations in designing siRNA that speciﬁcally
silences BimL, it is conceivable that this isoform also
contributes to PLX4720-induced apoptosis. More potent
inhibition of PLX4720-induced apoptosis by knockdown of
BimS was also demonstrated in another two B-RAF
V600E
melanoma cell lines (Supplementary Figure 6).
To further consolidate the role of BimS in induction of
apoptosis of mutant B-RAF melanoma cells, the GFP-tagged
open reading frame of human BimS cDNA cloned into the
pCMV6-AC vector (pCMV6-AC-BimS-GFP) was transiently
transfected into Mel-RMu and Mel-CV cells (Figure 5e).
Figure 5f shows that overexpression of BimS induced
apoptosis of the cells that could be detected as early as 16h
after transfection. By 48h, B50% of the cells in both cell lines
had committed to apoptosis. It is of note that BimS-GFP is
readily detected in mitochondrial fractions at 24h (Figure 5e),
consistent with previous reports that BimS-induced apoptosis
requires its mitochondrial localization.
17 As shown in
Figure 5g, exposure to PLX4720 similarly resulted in marked
relocationofendogenousBimS ontomitochondria inMel-RMu
and Mel-CV cells.
The SR protein SRp55 is involved in increased splicing
of BimS triggered by PLX4720 in B-RAF
V600E melanoma
cells. The gene encoding the SR protein SRp55, splicing
factor arginine/serine-rich 6 (SFRS6), has been shown to be
upregulated in B-RAF
V600E melanoma cells.
29 We therefore
studied whether SRp55 is involved in regulation of alternative
Figure 4 Enforced expression of B-RAF
V600E inhibited BimS expression in wild-type B-RAF melanoma cells and melanocytes. (a) Mel-RM and Me1007 cells were stably
transfected with cDNA encoding B-RAF carrying the V600E mutation. Whole cell lysates were subjected to western blot analysis of B-RAF, pERK1/2, and ERK1/2. The data
shown are representative of three individual western blot analyses. (b) Mel-RM and Me1007 cells were stably transfected with cDNA encoding B-RAF carrying the V600E
mutation. Cells were treated with SBHA (10mg/ml) for a further 16h. Total RNA was isolated and subjected to real-time PCR analysis for BimEL, BimL, and BimS mRNA
expression. The levels of the expression of individual species before treatment were arbitrarily designated as 1. The data shown are the mean±S.E. of three individual
experiments. (c) Whole cell lysates from Mel-RM and Me1007 cells treated as in b were subjected to western blot analysis of Bim and GAPDH (as a loading control).
The arrowhead points to nonspeciﬁc bands. The data shown are representative of three individual western blot analyses. (d) Melanocytes were transiently transfected
with cDNA encoding B-RAF carrying the V600E mutation. After 24h, whole cell lysates were subjected to western blot analysis of B-RAF, pERK1/2, ERK1/2, Bim, and Bcl-2.
The arrowhead points to nonspeciﬁc bands. The data shown are representative of three individual western blot analyses
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Cell Death and Diseasesplicing of Bim in B-RAF
V600E melanoma cells by inhibition
of B-RAF
V600E. Surprisingly, the levels of the SRp55 protein
appeared similar between B-RAF
V600E melanoma cell
lines and those in the wild-type B-RAF (Figure 6a). How-
ever, in response to treatment with PLX4720, the levels were
increased in B-RAF
V600E Mel-RMu cells, but not in wild-type
Mel-RM cells (Figure 6a). Similarly, treatment with PLX4720
resulted in a marked increase (ﬁvefold) in the expression
levels of the SFRS6 mRNA in Mel-RMu but not in Mel-RM
cells (Figure 6b).
We next transfected a siRNA pool for SFRS6 into Mel-RMu
and Mel-CV cells. Transfection of a siRNA pool for splicing
factor arginine/serine-rich 12 (SFRS12) was included as a
control (Figures 6c and d). Inhibition of SRp55 but not of
Figure 5 BimS has a critical role in PLX4720-induced apoptosis of mutant B-RAF melanoma cells. (a) Left panel: Mel-RMu and Mel-CV cells (B-RAF
V600E) were
transfectedwiththecontrolorBimsiRNA.After24h,cellsweretreatedwithPLX4720for16h.TotalRNAwasisolatedandsubjectedtoreal-timePCRanalysisforBimmRNA
expression. The relative abundance of mRNA expression in cells transfected with the control siRNA before treatment was arbitrarily designated as 1. Right panel: Mel-RMu
and Mel-CV cells were transfected with the control or Bim siRNA. After 24h, cells were treated with PLX4720 for a further 72h. Apoptosis was quantitated by the propidium
iodide(PI)method.Thedatashownarethemean±S.E.ofthreeindividualexperiments.(b)Mel-RMucellsweretransfectedwiththecontrol,BimEL,orBimSsiRNA.After24h,
cells were treated with PLX4720 (10mM) for 16h. Total RNA was isolated and subjected to real-time PCR analysis for BimEL (left panel) and BimS (right panel) mRNA
expression.ThelevelsoftheexpressionofindividualspeciesincellstransfectedwiththecontrolsiRNAwithouttreatmentwerearbitrarilydesignatedas1.Thedatashownare
the mean±S.E. of three individual experiments. (c) Whole cell lysates from Mel-RMu cells treated as in b were subjected to western blot analysis of Bim and GAPDH (as a
loading control). The arrowhead points to nonspeciﬁc bands. The data shown are representative of three individual western blot analyses. (d) Mel-RMu cells with BimEL or
BimS knocked down as in b were treated with PLX 4720 at 10mM for 72h. Apoptosis was quantitated by the PI method. The data shown are the mean±S.E. of three
individual experiments. (e) Left panel: Mel-RMu and Mel-CV cells were transfected with pCMV6-AC-GFP or pCMV6-AC-BimS-GFP. After 24h, whole cell lysates were
subjected to western blot analysis of BimS-GFP using an antibody against GFP. Western blot analysis of GAPDH was then performed as a loading control. Right panel:
Mel-RMu and Mel-CV cells were transfected with pCMV6-AC-GFP or pCMV6-AC-BimS-GFP. After 24h, mitochondrial fractions were subjected to western blot analysis of
BimS-GFPusinganantibodyagainstGFP.WesternblotanalysisofCOXIVwasthenperformedasaloadingcontrol.(f)Leftpanel:Representativeﬂowcytometrichistograms
of measurement of apoptosis using PE-conjugated Annexin-V in Mel-RMu and Mel-CV cells transfected with pCMV6-AC-GFP or pCMV6-AC-BimS-GFP. PE-positive cells
were quantitated in gated GFP-positive cell populations. The numbers represent percentages of positive cells. Right panel: Mel-RMu and Mel-CV cells were transfected with
pCMV6-AC-GFP or pCMV6-AC-BimS-GFP for indicated time periods. Apoptotic cells were quantitated with PE-conjugated Annexin-V in gated GFP-positive cell populations.
The data shown are representative of two experiments. (g) Mitochondrial fractions from Mel-RMu and Mel-CV cells treated with PLX4720 (10mM) for indicated time periods
were subjected to western blot analysis of Bim and COX IV (as a control). The data shown are representative of three individual western blot analyses
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Cell Death and DiseaseSRrp86, blocked the increase in the BimS mRNA and protein,
and the increases in the ratios of the BimS mRNA to the BimEL
and BimL mRNAs was induced by PLX4720 (Figures 6e–g).
This was associated with attenuation of PLX4720-induced
killing inboth Mel-RMu and Mel-CV cells(Figure 6h).Figure 6i
shows that overexpression of SRp55 resulted in moderate
levels of apoptosis in Mel-RMu and Mel-CV cells in the
absenceofany furthertreatment. Thiswas associatedwith an
increase in BimS to varying degrees in Mel-RMu and Mel-CV
cells (Figure 6i).
PLX4720 preferentially increases BimS and induces
apoptosis in fresh melanoma isolates carrying
B-RAF
V600E. As shown in Figure 7a, PLX4720 inhibited
activation of ERK1/2 in two fresh isolates with B-RAF
V600E
but not in the one with wild-type B-RAF. Consistently,
PLX4720 markedly reduced the viability of the B-RAF
V600E
cells but not of wild-type B-RAF cells (Figure 7b). Two
B-RAF
V600E fresh isolates were used for further studies.
PLX4720 upregulated the three Bim mRNA species in
both fresh isolates (Figure 7c). It also upregulated all three
protein variants, except for BimL, in Mel-JG cells (Figure 7c).
Notably, there were also discrepancies in the levels of other
mRNA species and corresponding protein variants after
treatment with PLX4720. This suggests that mechanisms
other than those mediated by inhibition of B-RAF
V600E may
be involved in regulation of the expression of Bim protein
variants. Nevertheless, similar to results with melanoma cell
lines, PLX4720 triggered increases in the ratios of the BimS
mRNA to the BimEL and BimL mRNAs in both fresh isolates
(Figure 8a). This was associated with an increase in
the levels of the SRp55 protein and the SFRS6 mRNA
(Figure 8b). Inhibition of BimS by siRNA partially restored
viability of the cells, whereas inhibition of SRp55 by siRNA
blocked the increase in BimS and similarly inhibited killing
induced by PLX4720 (Figure 8c).
Discussion
The above results extend the role of Bim in apoptosis induced
by inhibition of B-RAF
V600E beyond upregulation of BimEL by
showing that PLX4720 triggers preferential splicing to
produce BimS, which has a greater part in induction of
apoptosis than BimEL.
7,8 In addition, the results demonstrate
thattheincreaseinsplicingofBimSisduetoamechanismthat
isregulatedbythesplicingfactorSRp55,whichisincreasedin
B-RAF
V600E melanoma cells by PLX4720.
In support of previous observations,
30 BimEL was upregu-
lated by PLX4720 in B-RAF-mutant melanoma cells, which
was associated with a reduction in the levels of an extra band
with reduced electrophoretic motility that corresponds to
Figure 5 Continued
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Cell Death and Diseasephosphorylated BimEL.
13 This was consistent with inhibition of
activation of ERK1/2 by PLX4720,
5 in that ERK1/2 can
phosphorylate BimEL, thereby causing its ubiquitination and
degradation by the proteasome system.
13 Inhibition of this
pathwayhasbeensuggestedtoaccountforamajorpartofthe
accumulation of BimEL.
13,30 Strikingly, BimL, and in particular,
Figure 6 SRp55 has a role in upregulation of BimS by PLX4720. (a) Left panel: whole cell lysates from a panel of mutant and wild-type B-RAF melanoma cell lines were
subjected towesternblotanalysisof SRp55andGAPDH(asaloadingcontrol).Rightpanel:wholecelllysatesfromMel-RMandMel-RMucellstreatedwithPLX4720(10mM)
for indicated time periods were subjected to western blot analysis of SRp55 and GAPDH (as a loading control). The data shown are representativeof three individual western
blot analyses. (b) Total RNA from Mel-RM and Mel-RMu cells treated with PLX4720 (10mM) for 16h was isolated and subjected to real-time PCR analysis for SFRS6. The
relative abundance of mRNA expression before treatment was arbitrarily designated as 1. The data shown are the mean±S.E. of three individual experiments. (c) Mutant
B-RAFMel-RMuandMel-CVcellsweretransfectedwiththecontrol,SFRS6,andSFRS12siRNAs.After24h,totalRNAwasisolatedandsubjectedtoreal-timePCRanalysis
for SFRS6 and SFRS12 mRNA expression. The relative abundance of mRNA expression in cells transfected with the control siRNA was arbitrarily designated as 1. The data
shown are the mean±S.E. of three individual experiments. (d) Whole cell lysates from cells treated as in c were subjected to western blot analysis of SRp55, SRrp86, and
GAPDH (as a loading control). The data shown are representative of three individual western blot analyses. (e) Mel-RMu and Mel-CV cells were transfected with the control,
SFRS6,andSFRS12siRNAs.After24h,cellsweretreatedwithPLX4720(10mM)forafurther16h.TotalRNAwasisolatedandsubjectedtoreal-timePCRanalysisforBimS
mRNA expression. The relative abundance of mRNA expression in cells transfected with the control siRNA without treatment with PLX4720 was arbitrarily designated as 1,
which was not shown. The data shown are the mean±S.E. of three individual experiments. (f) Mel-RMu and Mel-CV cells were transfected with the control, SFRS6, and
SFRS12 siRNA. After 24h, total RNA was isolated and subjected to real-time PCR analysis for BimEL, BimL, and BimS mRNA expression. Left panel: the ratios between the
levelsofBimSmRNAandBimELmRNAbeforeandaftertreatment,respectively,werecalculatedas(DDCtofBimS/DDCtofBimEL).Rightpanel:theratiosbetweenthelevels
of BimS mRNA and BimL mRNA before and after treatment, respectively, were calculated as (DDCt of BimS/DDCt of BimL). The data shown are the mean±S.E. of three
individual experiments. (g) Mel-RMu and Mel-CV cells were transfected with the control and SFRS6 siRNA, respectively. After 24h later, whole cell lysates were subjected to
western blot analysis of Bim and GAPDH (as a loading control). The arrowhead points to nonspeciﬁc bands generated by the antibody against Bim. The data shown are
representative of three individual western blot analyses. (h) Mel-RMu and Mel-CV cells were transfected with the control, SFRS6, and SFRS12 siRNA. After 24h, cells were
treated with PLX4720 (10mM) for a further 72h. Apoptosis was quantitated by the propidium iodide (PI) method. The data shown are the mean±S.E. of three individual
experiments.(i)Leftpanel:Mel-RmuandMel-CVcellsweretransfectedwithwithpCMV6-AC-GFPorpCMV6-AC-SFRS6-GFP.After48h,cellswereharvestedandapoptosis
was measured with PE-conjugated Annexin-V in gated GFP-positive cell populations. The data shown are representative of two experiments. Right panel: Mel-Rmu and
Mel-CVcellsweretransfectedwithwithpCMV6-AC-GFPorpCMV6-AC-SFRS6-GFP.After24h,wholecelllysatesweresubjectedtowesternblotanalysisofSRp55-GFPand
BimS. The arrowhead points to nonspeciﬁc bands. Western blot analysis of GAPDH was then performed as a loading control. The data shown are representative of three
individual western blot analyses
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Cell Death and DiseaseBimS, were also increased by PLX4720 in B-RAF
V600E
melanoma cells. Nevertheless, the kinetics and sustainability
of upregulation of the three Bim isoforms varied from one
another, suggesting that the mechanisms responsible for
upregulation of the individual proteins may be different.
The marked increase in BimS induced by PLX4720 is of
particular interest, in that BimS is rarely detectable at the
protein level in cells.
13,16 This is presumably associated with
its stronger potency in induction of apoptosis than other
isoforms, as BimS is not subject to any posttranslational
regulation and is instantly activated once it is expressed.
13
When overexpressed, BimS can rapidly translocate onto the
mitochondrial outer membrane where it recruits and activates
Bax independently of inhibition of anti-apoptotic Bcl-2 family
proteins.
17 Further studies by real-time revealed that the
BimS transcript was preferentially induced by PLX4720 in
B-RAF
V600E melanoma cells. Moreover, the preferential
induction of splicing to produce BimS seemed to be speciﬁc
for PLX4720, as treatment of B-RAF
V600E melanoma cells
with the histone deacetylase inhibitor SBHA, which is known
to increase transcription of Bim, did not cause selective
upregulation of the BimS transcript, although the levels of all
three mRNA species were increased.
28 The preferential
splicing to produce BimS is of functional signiﬁcance, in that
speciﬁc inhibition of BimS resulted in a greater degree of
inhibition of PLX4720-induced killing than selective inhibition
of BimEL.
The preferential induction of splicing of BimS suggests that
the mutant B-RAF
V600E may regulate Bim alternative splicing
in melanoma cells, and in particular, may suppress splicing to
produce BimS. This was supported by the ﬁnding that
enforced expression of B-RAF
V600E in wild-type B-RAF
melanoma cells blocked upregulation of the BimS transcript
by SBHA, but had no effect on upregulation of the BimEL
and BimL mRNA. Furthermore, enforced expression of
B-RAF
V600E in melanocytes resulted in decreases in the
BimSmRNAandprotein,butintriguingly,thelevelsoftheBimL
mRNA and protein were increased by enforced expression of
B-RAF
V600E These results suggest that regulation of Bim
splicing by mutant B-RAF is more complex than inhibition of
splicing of BimS, and may vary between different cell types. It
is of interest that, in contrast to melanoma cells, melanocytes
expressed readily detectable levels of BimS together with
BimEL and BimL. This may indicate that BimS expression is
Figure 6 Continued
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Cell Death and Diseaselost during melanoma development as a consequence of
mutations in B-RAF. Bim has been shown to be decreased
with melanoma progression.
31
Altered splicing patterns, in particular, changes in splicing
patterns of apoptosis-related genes, are frequently found in
various cancers.
20,21,23 Although the mechanisms underlying
this remain unclear, it is well established that alternative
splicing is tightly regulated by splicing factors, including the
SR and hnRNP protein families.
25,27,32 There is a growing
body of evidence showing that some protein kinases such as
Figure 7 PLX4720 inhibits activation of ERK1/2, reduces cell viability, upregulates BimS, increases the ratios of BimS mRNA to BimEL and BimL mRNA, and upregulates
SRp55 in mutant B-RAF fresh melanoma isolates. (a) Whole cell lysates from fresh melanoma isolates harboring mutant B-RAF (Mel-JR, Mel-JG, and Mel-EK) or wild-type
B-RAF(Mel-BE)treatedwithPLX4720(10mM)for16hweresubjectedtowesternblotanalysisofpERK1/2andERK1/2.Thedatashownarerepresentativeofthreeindividual
western blot analyses. (b) Fresh melanoma isolates were treated with PLX4720 (10mM) for 72h before cell viability was quantitated by MTS assays. The data shown are the
mean±S.E.of threeindividualexperiments. (c)Leftpanel: freshlyisolatedMel-JRandMel-JGcellsweretreatedwith PLX4720(10mM) for 16h.TotalRNAwas isolatedand
subjected to real-time PCR analysis for BimEL, BimL, and BimS mRNA expression. The levels of the expression of individual species before treatment were arbitrarily
designatedas1.Rightpanel:wholecelllysatesfromfreshlyisolatedMel-JRandMel-JGcellstreatedwithPLX4720(10mM)for16hweresubjectedtowesternblotanalysisof
Bim and GAPDH (as a loading control). The arrowhead points to nonspeciﬁc bands. The data shown are either representative (right panel) or the mean±S.E. (left panel) of
threeindividualexperiments.(d)FreshlyisolatedMel-JRandMel-JGcellsweretreatedwithPLX4720(10mM)for16h.TotalRNAwasisolatedandsubjectedtoreal-timePCR
analysisforBimEL,BimL,andBimSmRNAexpression.TheratiosbetweenthelevelsofBimSmRNAandBimELmRNAbeforeandaftertreatment,respectively,werecalculated
as (DDCt of BimS/DDCt of BimEL), and the ratios between the levels of BimS mRNA and BimL mRNA before and after treatment, respectively, were calculated as (DDCto f
BimS/DDCt of BimL). Thedata shownare the mean±S.E. of threeindividualexperiments.(e)Upper panel: totalRNAfrom Mel-JRand Mel-JGcellstreatedwith PLX4720as
inawas subjectedtoreal-timePCRanalysisforSFRS6mRNAexpression.Therelativeabundance ofSFRS6mRNAincellsbefore treatmentwasarbitrarilydesignatedas 1.
Lower panel: whole cell lysates from Mel-JR and Mel-JG cells treated as given above were subjected to western blot analysis of SRp55 and GAPDH (as a loading control).
The data shown are either representative (lower panel) or the mean±S.E. (upper panel) of three individual experiments
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Cell Death and DiseaseAkt and ERK1/2 that have important roles in cancer
development also have roles in regulation of activity of SR
proteins, probably by modulating their phosphorylation
status.
33–35 In this study, we found that one of the SR
proteins, SRp55, was associated with preferential splicing to
produce BimS after inhibition of mutant B-RAF by PLX4720.
This was demonstrated by the ﬁndings that PLX4720
upregulated SRp55, and that inhibition of SRp55 with siRNA
blocked upregulation of the BimS transcript and reversed
the increases in ratios of the BimS mRNA to the BimEL and
BimL mRNA induced by PLX4720. Consistently, knockdown
of SRp55 partially inhibited apoptosis induced by PLX4720
in mutant B-RAF melanoma cells. Therefore, the mutant
B-RAF
V600E appears to regulate the expression of SRp55 that
in turn has a role in regulating alternative splicing of Bim, in
particular, in promoting splicing to produce BimS.
The ﬁnding that killing of mutant B-RAF fresh melanoma
isolates by PLX4720 was similarly associated with upregula-
tion of Bim, in particular, BimS, is of particular importance, in
that this may reﬂect more closely the reaction of melanoma
cells in vivo to treatment with B-RAF inhibitors. Together, the
results reported in this study identify induction of BimS as a
key mechanism for induction of apoptosis by PLX4720 in
melanoma cells carrying B-RAF
V600E. We speculate that this
may be critical for long-term clinical responses to the inhibitor.
Plasma concentrations of PLX4032 of around 60mM were
apparently not associated with signiﬁcant adverse effects in
phase I clinical trials with PLX4032,
1 suggesting that the
concentrations used in this study are achievable clinically.
Materials and Methods
Cell lines. Human melanoma cell lines Mel-RM, Me1007, Mel-RMu, MM200,
Mel-CV, and Sk-Mel-110 have been described previously.
36,37 They were cultured
inDMEMcontaining5%FCS(CommonwealthSerumLaboratories,Melbourne,Vic,
Australia).MelanocyteswerekindlyprovidedbyDrPParsons(QueenslandInstitute
of Medical Research, Qld, Australia) and cultured in medium supplied by Clonetics
(Edward Kellar, Vic, Australia).
Fresh melanoma isolates. Isolation of melanoma cells from fresh surgical
specimens was carried out as described previously.
38 Protocols were approved by
the Human Research Ethics Committee of Hunter New England Health, Australia.
Antibodies, recombinant proteins, and other reagents. PLX4720
was provided from Plexxikon Inc (Berkeley, CA, USA). It was dissolved in DMSO
and made up in stock solutions of 4mM. Actinomycin D and SBHA were purchased
from Sigma-Aldrich (Castle Hill, NSW, Australia). SBHA was dissolved in distilled
waterandmadeupinastocksolutionof10mg/ml.ThemouseMAbsagainstpERK,
Bcl-2, Mcl-1, Bad, and AIF, and the rabbit polyclonal antibodies (Abs) against
B-RAF were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The MAb against Noxa and the polyclonal Ab against Bim were purchased from
Imgenex (San Diego, CA, USA). The rabbit polyclonal Abs against PUMA, ERK,
COX IV, A-RAF, C-RAF, and Bid were from Cell Signalling Technology (Beverly,
Figure 8 Inhibition of BimS by siRNA reverses the reduction in cell viability induced by PLX4720, whereas inhibition of SRp55 blocks induction of BimS and induction of
apoptosisbyPLX4720inmutantB-RAFfreshmelanomaisolates.(a)Leftpanel:Mel-JRandMel-JGcellsweretransfectedwiththecontrolandBimSsiRNA,respectively.After
24h,wholecelllysatesweresubjectedtowesternblotanalysisofBimandGAPDH(asaloadingcontrol).Thearrowheadpointstononspeciﬁcbands.Rightpanel:Mel-JRand
Mel-JG cells were transfected with the control and BimS siRNA, respectively. After 24h, cells were treated with PLX4720 (10mM) for a further 72h. Apoptosis was measured
by the propidium iodide (PI) method. The data shown are either representative (left panel) or the mean±S.E. (right panel) of three individual experiments. (b) Mel-JR and
Mel-JG cells were transfected with the control and SFRS6 siRNA, respectively. After 24h, cells were treated with PLX4720 (10mM) for a further 16h. Whole cell lysates were
subjectedto western blot analysisof SRp55,Bim, and GAPDH (as a loading control). Thearrowhead points to nonspeciﬁcbands. The data shown are representative of three
individualwesternblot analyses.(c)TotalRNAfromMel-JRandMel-JGcellstreatedasinbwassubjectedto real-timePCRanalysisfor BimSmRNAexpression.Therelative
abundance of BimS mRNA in cells transfected with the control siRNA without treatment with PLX4720 was designated as 1, which was not shown. The data shown are the
mean±S.E. of threeindividualexperiments.(d)Mel-JRand Mel-JGcellsweretransfected with thecontrolandSFRS6siRNA, respectively. After24h, cells weretreatedwith
PLX4720(10mM) for afurther 72h. Apoptosiswas quantitated by thePI method. Thedatashown are eitherthemean±S.E.(right panel of a, c, andd) or representative (left
panel of a and b) of three individual experiments. The data shown are the mean±S.E. of three individual experiments
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Cell Death and DiseaseMA, USA). The rabbit polyclonal Abs against SFRS6, SFRS12, and b-actin were
from Sigma-Aldrich. The mouse MAbs against cytochrome c, PARP were from
Pharmingen (Bioclone, Marrickville, NSW, Australia). The rabbit polyclonal anti-Bax
against amino acids 1 through to 20 was purchased from Upstate Biotechnology
(Lake Placid, NY, USA). The mouse MAb against Bak (Ab-1) was purchased from
Calbiochem (La Jolla, CA, USA). The mouse MAb against caspase-7 and therabbit
polyclonal Ab against caspase-3 were from Stressgen (Victoria, BC, Canada). The
cell-permeable general caspase inhibitor Z-Val-Ala-Asp(OMe)-CH2F (z-VAD-fmk)
was purchased from Calbiochem. Isotype control Abs used were the ID4.5 (mouse
IgG2a)MAbagainstSalmonellatyphisuppliedbyDrLAshman(InstituteforMedical
and Veterinary Science, Adelaide, Australia), the 107.3 mouse IgG1 MAb
purchased from PharMingen (San Diego, CA, USA), and rabbit IgG from
Sigma-Aldrich .
Cell viability assays (MTS assays). The cytotoxic effect of PLX4720 on
melanomacells was determined using VisionBlueFluorescence Cell ViabilityAssay
Kit(BiovisionInc.,MountainView,CA,USA)asdescribedpreviously.
38Brieﬂy,cells
were seeded at 5000 cells per well onto ﬂat-bottomed 96-well culture plates and
allowed to grow for 24h followed by the desired treatment. Cells were then labeled
withtheVisionBluereagentanddetectedbySynergytwomulti-detection microplate
reader (BioTek, Winooski, VT, USA) according to the manufacturer’s instructions.
Apoptosis. Quantitation of apoptotic cells by measurement of sub-G1 DNA
contentusingthepropidiumiodide(Sigma-Aldrich)methodorbyAnnexin-Vstaining
was carried out as described elsewhere.
36,37
Western blot analysis. Western blot analysis was carried out as
described previously.
36,37 Labeled bands were detected by Immun-Star HRP
Chemiluminescent Kit, and images were captured and the intensity of the bands
was quantitated with the Bio-RadVersaDoc image system (Bio-Rad, RegentsPark,
NSW, Australia).
Preparation of mitochondrial and cytosolic fractions. The
mitochondrial and cytosolic fractions were prepared by using Qproteome
Mitochondrial Isolation Kit (Qiagen, Doncaster, Vic, Australia) according to the
manufacturer’s instruction. In brief, after trypsinization, cells were washed with PBS
and followed by 0.9% sodium chloride solution. Cell pellets were resuspended in
ice-cold lysis buffer and incubated for 10min at 41C on an end-over-end shaker.
After incubation, cell lysates were spun at 1000 g for 10min at 41C and the
supernatant for cytosolic fraction was collected. Cell pellets were resuspended in
disruption buffer, puriﬁcation buffer, and followed by storage buffer with spins
in between. The mitochondrial pellets were ﬁnally resuspended in lysis buffer for
western blot analysis.
Plasmid vector and transfection. Stable Mel-RMu and Mel-CV
transfectants of Bcl-2 were established by electroporation of the pEF-puro vector
carrying human Bcl-2 cDNA provided by Dr David Vaux (Walter and Eliza Hall
Institute, Melbourne, Vic, Australia) and described elsewhere.
39 The pCDH-CMV-
MCS-EF1-Puro (CD510B-1) vector carrying B-RAF
V600E cDNA was kindly provided
by Professor Richard Marais (The Institute of Cancer Research, UK). The pCMV6-
AC-BimS-GFP vector and the pCMV6-AC-SFRS6-GFP vector were purchased
from OriGene (Rockville, MD, USA). Melanoma cells were seeded at 1 10
5 cells
per well in 24-well plate, 24h before transfection. Cells were transfected with
1mg plasmid as well as the empty vector (Sigma-Aldrich) in Opti-MEM medium
(Invitrogen, Carlsbad, CA, USA) with Lipofectamine 2000 reagent (Invitrogen),
according to the manufacturer’s protocol. At 6h after transfection, the cells were
switched into antibiotic-free medium containing 5% FCS for a further 24h. Cells
were then passaged at 1:10 ratio into fresh medium for further 24h, followed by
G418 or puromycin (Sigma-Aldrich) selection.
Real-time PCR. Real-time PCR was performed using the ABI Fast 7900HT
sequence detection system (Applied Biosystems, Foster City, CA, USA). For Bim
mRNA detection, 25ml mixture was used for reaction, which contains 5ml cDNA
sample (0.5–1mg/ml), 300nM forward primers for Bim 50-TGCAGACATTTTG
CTTGTTCAA-30 and b-actin 50-GGCACCCAGCACAATGAAG-30, 300nM reverse
primers for Bim 50-GAACCGCTGGCTGCATAATAAT-30 and b-actin 50-GCCGAT
CCACACGGAGTACT-30, 200nM probes for Bim 6FAM-CCAACAAGACCCAG
CACCGCG-TAMRA and b-actin 6FAM-TCAAGATCATTGCTCCTCCTGAGCGC-
TAMRA, and 9mM MgCI2. To speciﬁcally detect individual Bim isoforms, forward
primers were designed to span the junctions of exons 3 and 4, exons 2 and 4, and
exons 4 and 5, which are unique to BimEL, BimL, and BimS, respectively. BimEL
forward primer is 50-GTGGGTATTTCTCTTTTGACACAGAC-30, BimL forward
primer is 50-TACAGACAGAGCCACAAGACAG-30, and common reverse primer
for both BimEL and BimL is 50-GTTCAGCCTGCCTCATGGAAG-30; BimS forward
primer is 50-TGACCGAGAAGGTAGACAAT-30, BimS reverse primer is 50-GCCA
TACAAATCTAAGCCAGT-30. Real-time PCR for three Bim isoforms was done by
Fast SYBR Green Master Mix (Applied Biosystems). For SFRS6 and SFRS12,
assay-on-demand for SFRS6 (assay ID: Hs00740177_g1), SFRS12 (assay ID:
Hs00377948_m1), and GAPDH (assay ID: Hs99999905_m1) were used according
to manufacturer’s protocol (Applied Biosystems). Analysis of cDNA for b-actin or
GAPDH was included as a control. The threshold cycle value (Ct) was normalized
against b-actin or GAPDH cycle numbers. The relative abundance of mRNA
expressionofacontrolsamplewasarbitrarilydesignatedas1,andthevaluesofthe
relative abundance of mRNA of other samples were calculated accordingly.
Small interfering RNA . The siRNA constructs for Bim, B-RAF, SFRS6, and
SFRS12 were obtained as the siGENOME SMARTpool reagents (Dharmacon,
Lafayette, CO, USA), the siGENOME SMARTpool Bim (M-004383-01-0010),
the siGENOME SMARTpool B-RAF (M-003460-03-0010), the siGENOME
SMARTpool SFRS6 (M-016067-01-0010), and the siGENOME SMARTpool
SFRS12 (M-016865-01-0010). The nontargeting siRNA control, SiConTRolNon-
targeting SiRNA pool (D-001206-13-20) was also obtained from Dharmacon.
To speciﬁcally knockdown BimEL and BimS, siRNAs were designed to target
exons 3 and 5, which are unique to BimEL and BimS, respectively. The oligonucleo-
tides used were BimEL sense 50-CUGCUGUCUCGAUCCUCCAdTdT-30, BimEL
antisense50-UGGAGGAUCGAGACAGCAGdTdT-30;Bi m Ssense50-CAUAUGGUCA
UUGGUGAUUdTdT-30,B i m S antisense 50-AAUCACCAAUGACCAUAUGdTdT-30;
control sense 50-GGCUGUAACUUACGUGUACUUdTdT-30,c o n t r o la n t i s e n s e ,
50-AAGUACACGUAAGUUACAGCCdTdT-30. Transfection of siRNA pools was
carried out as described previously.
39
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